TKM-080301
Phase 1/2Completed 0 watching 0 views this week๐ค Quiet
36
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancer
Conditions
Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
Trial Timeline
Dec 1, 2010 โ Aug 1, 2015
NCT ID
NCT01262235About TKM-080301
TKM-080301 is a phase 1/2 stage product being developed by Arbutus Biopharma for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01262235. Target conditions include Cancer, Neuroendocrine Tumors, NET.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02191878 | Phase 1/2 | Completed |
| NCT01262235 | Phase 1/2 | Completed |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7389 | Eisai | Phase 1 | 33 |
| Veliparib | AbbVie | Phase 2 | 52 |
| AK-105 | Akeso | Phase 1 | 32 |
| XL820 | Exelixis | Phase 1 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 33 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 23 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT | Nanobiotix | Phase 1/2 | 36 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |